Ojjaara (momelotinib) — Medica
Myelofibrosis (intermediate-risk or high-risk), including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis
Initial criteria
- age ≥ 18 years
- disease is intermediate-risk or high-risk
- Patient meets ONE of the following:
- 1) Patient has anemia AND both of the following:
- a) hemoglobin < 10 g/dL
- b) symptomatic splenomegaly and/or constitutional symptoms (e.g., weight loss, night sweats, fever)
- OR 2) platelet count ≥ 50 x 10^9/L
Approval duration
1 year